☆ 4.7 Article

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

LANCET ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio et al.

Summary: The IMpower132 study demonstrated significant improvement in PFS with APP compared to PP, but the difference in OS between the two groups was not statistically significant. APP showed favorable OS and PFS results across subgroups, with a manageable safety profile and no new or unexpected safety signals identified.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou et al.

Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

M. Johnson et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Article Oncology

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

Jie Wang et al.

Summary: This study showed that tislelizumab combined with chemotherapy can significantly improve progression-free survival in patients with advanced squamous non-small-cell lung cancer, providing potential benefits in clinical practice.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lu et al.

Summary: The addition of tislelizumab to chemotherapy in patients with advanced nonsquamous NSCLC resulted in significantly prolonged progression-free survival (PFS), higher response rates, and longer response duration compared with chemotherapy alone, indicating a promising new option for first-line treatment regardless of disease stage.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou et al.

Summary: A randomized, double-blind, phase 3 study found that Sintilimab plus GP showed better progression-free survival compared to GP alone in first-line treatment for patients with locally advanced or metastatic sqNSCLC. The toxicity of the treatment was acceptable, and no new unexpected safety signals were observed.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert Jotte et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation

Juan Zhang et al.

CANCER RESEARCH (2020)

Add to Collection

Meeting Abstract Oncology

GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

C. Zhou et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis

Xiangjiao Meng et al.

CLINICAL LUNG CANCER (2019)

Add to Collection

Article Oncology

Management of Immunotherapy-Related Toxicities. Version 1.2019

John A. Thompson et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

Add to Collection

Review Oncology

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

Urania Dafni et al.

LUNG CANCER (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Abandoning the Notion of Non-Small Cell Lung Cancer

Valeria Relli et al.

TRENDS IN MOLECULAR MEDICINE (2019)

Add to Collection

Review Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis

Yucai Wang et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Mark A. Socinski et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)

Paul W. Sperduto et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014

Daniel Morgensztern et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.